In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eisai licenses Dainippon's diabetic neuropathy candidate

Executive Summary

Dainippon Sumitomo Pharma (formerly Dainippon Pharmaceutical) licensed Eisai the exclusive development, manufacturing, and co-promotion rights to AS3201 (ranirestat), worldwide except for Japan. The candidate is an aldose reductase inhibitor for diabetic neuropathy.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies